Dana-Farber to retract six papers, correct 31, over “image discrepancies” in papers co-authored by top leaders

Dario C. Altieri joins Sidney Kimmel Jefferson as professor

Dario C. Altieri has joined the faculty of Sidney Kimmel Medical College, effective Jan. 1, 2027, following completion of his leadership tenure at The Wistar Institute, Thomas Jefferson University has announced.

May 22, 2026

Vol.52 No.20

In Brief

Abu Dhabi health authorities, Fred Hutch collaborate on cancer research and personalized prevention

The Department of Health Abu Dhabi, regulator of the healthcare sector in the emirate, together with the Abu Dhabi Public Health Center, announced the execution of a Memorandum of Understanding with Fred Hutchinson Cancer Center.

May 15, 2026

Vol.52 No.19

Collaborative work behind the scenes makes cancer breakthroughs possible

When we talk about breakthroughs in cancer research, most focus on the moment of discovery: a new therapy, a promising trial result, or a headline-grabbing study.

May 08, 2026

Vol.52 No.18

By Annaliese Daniels

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

University of Maryland Greenebaum Comprehensive Cancer Center receives $5.5M donation to advance cancer research and patient care

The Marlene and Stewart Greenebaum Family Foundation has donated $5.5 million to the University of Maryland Greenebaum Comprehensive Cancer Center to help advance scientific research and cancer care in Maryland and across the region.

April 17, 2026

Vol.52 No.15

Guest Editorial

America needs a new blueprint for the National Cancer Program
First step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”

Recently, a friend lent me a copy of a decades-old report, and by old, I mean a classic.

April 10, 2026

Vol.52 No.14

By Robert A. Winn

Dana-Farber to retract six papers, correct 31, over “image discrepancies” in papers co-authored by top leaders

YOU MAY BE INTERESTED IN

Dario C. Altieri joins Sidney Kimmel Jefferson as professor

Abu Dhabi health authorities, Fred Hutch collaborate on cancer research and personalized prevention

Collaborative work behind the scenes makes cancer breakthroughs possible

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

University of Maryland Greenebaum Comprehensive Cancer Center receives $5.5M donation to advance cancer research and patient care

America needs a new blueprint for the National Cancer Program
First step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”

Renew today!

Subscriber content

Never miss an issue!

Login

Dana-Farber to retract six papers, correct 31, over “image discrepancies” in papers co-authored by top leaders

YOU MAY BE INTERESTED IN

Dario C. Altieri joins Sidney Kimmel Jefferson as professor

Abu Dhabi health authorities, Fred Hutch collaborate on cancer research and personalized prevention

Collaborative work behind the scenes makes cancer breakthroughs possible

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

University of Maryland Greenebaum Comprehensive Cancer Center receives $5.5M donation to advance cancer research and patient care

America needs a new blueprint for the National Cancer ProgramFirst step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

America needs a new blueprint for the National Cancer Program
First step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”